What question did this study set out to answer?

The aim is to evaluate the effectiveness of cemiplimab in treating advanced cutaneous squamous cell carcinoma in elderly patients with multiple health conditions.

May 8, 2026Open Access

Treatment of advanced cutaneous squamous cell carcinoma with cemiplimab in elderly multimorbid patients – a case series

Key Points

The aim is to evaluate the effectiveness of cemiplimab in treating advanced cutaneous squamous cell carcinoma in elderly patients with multiple health conditions.
Case series design focusing on elderly multimorbid patients
Intervention involving cemiplimab administration for cancer treatment
Assessment of patient outcomes and treatment responses
Cemiplimab showed promising efficacy in reducing tumor size in elderly patients.
Most patients tolerated the treatment well without significant adverse effects.
Long-term follow-up demonstrated durable responses in several cases.

Abstract

PP: Speaker honoraria and travel support from BMS, Pierre Fabre. KA: Speaker honoraria and travel support from BMS, Pierre Fabre, Novartis. MPS: Speaker honoraria and consultancy fees from AbbVie, Almirall, Biogen, BMS, Janssen, Lilly, Novartis, Scinai, UCB. KMT: Speaker honoraria and consultancy fees or travel support from BMS, MSD, Pierre Fabre, Novartis, Regeneron, Sanofi, Immunocore, Sun Pharma, Amgen, LEO Pharma, Galderma, Almirall, Lilly, Abbvie, Johnson & Johnson, Candela.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Porebski et al. (Wed,) studied this question.

synapsesocial.com/papers/69fd7e90bfa21ec5bbf06d6f https://doi.org/https://doi.org/10.1111/ddg.70312x

Bookmark

View Full Paper